No Data
No Data
Soligenix Begins Patient Enrollment for Phase 3 Study of Drug Candidate for Cutaneous T-Cell Lymphoma
EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer
EXCLUSIVE: Soligenix Tells Benzinga Co. Initiates Confirmatory Phase III Trial Of HyBryte For The Treatment Of Cutaneous T-Cell Lymphoma
Soligenix Announced That Analysis Of The Post-treatment Data From The Open-label Study Comparing HyBryte (Synthetic Hypericin) To Valchlor (Mechlorethamine) Has Demonstrated Continued Improvement In HyBryte-treated Patients And Their Individual...
Express News | Soligenix Inc: Hybryte Was Well Tolerated in All Patients
Express News | Soligenix: 1 Of 5 Patients Receiving Valchlor Had to Be Withdrawn From Trial Due to a Clinically Significant Allergic Contact Dermatitis